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Case Report
Acute Presentation and Persistent Glomerulonephritis Following
Streptococcal Infection in a Patient With Heterozygous
Complement Factor H–Related Protein 5 Deficiency
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Acute poststreptococcal glomerulonephritis is a common cause of acute nephritis in children. Transient
hypocomplementemia and complete recovery are typical, with only a minority developing chronic disease. We
describe a young girl who developed persistent kidney disease and hypocomplementemia after a streptococcal
throat infection. Kidney biopsy 1 year after presentation showed isolated glomerular complement C3 deposi-
tion, membranoproliferative changes, and subendothelial, intramembranous and occasional subepithelial
electron-dense deposits consistent with C3 glomerulopathy. Complement gene screening revealed a heterozy-
gous single nucleotide insertion in exon 4 of the complement factor H–related protein 5 gene (CFHR5),
resulting in a premature stop codon. This variant was not detected in 198 controls. Serum CFHR5 levels were
reduced. The mother and sister of the index patient were heterozygous for the sequence variant, with no overt
evidence of kidney disease. We speculate that this heterozygous CFHR5 sequence variant is a risk factor for
the development of chronic kidney disease after streptococcal infection.
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INDEX WORDS: Complement; kidney; streptococcus; C3 glomerulopathy.Acute poststreptococcal glomerulonephritis(APSGN) is a common cause of childhood
acute nephritis. Serum complement C3, C5, and pro-
perdin levels typically are reduced acutely, whereas
C4 levels are normal.1,2 This pattern of hypocomple-
mentemia reflects selective activation of the comple-
ment alternative pathway. Streptococcal components
have been shown to activate this pathway,3-5 and
transient C3 nephritic factor (C3NeF) has been shown
in some cases.6 C3NeF potentiates activation of the
alternative pathway and typically is seen in dense
deposit disease, a condition strongly associated with
alternative pathway dysregulation. In APSGN, most
children recover completely and complement levels
return to normal within 12 weeks. For reasons that are
unknown, a minority develop chronic kidney disease
associated with continuing hypocomplementemia.7,8
We report a case of persistent kidney disease after
streptococcal infection in association with a heterozy-
gous mutation in the gene encoding complement
factor H–related protein 5 (CFHR5).
CASE REPORT
A previously healthy 7-year-old Caucasian female presented
with a 10-day history of lethargy, fever, sore throat, and cough
associated with abdominal pain, vomiting, and dark colored urine.
Mild periorbital edema was accompanied by abnormal urinalysis
results (protein [3], blood [3]). Results of investigations in-
cluded the following values: serum urea nitrogen, 50.1 mg/dL
(17.9 mmol/L); creatinine, 0.98 mg/dL (87 mol/L); hemoglobin,
10.9 g/dL (109 g/L); C-reactive protein, 77 mg/L; C3, 0.36 mg/mL
(0.36 g/L; reference range, 0.75-1.65); C4, 0.29 mg/mL (0.29 g/L;
Am J Kidney Dis. 2012;60(1):121-125reference range, 0.11-0.43); and urine protein-creatinine ratio,
5,221 mg/g. Both serum anti-streptolysin O (200 U/mL) and
anti-DNase antibody titers (360 U/mL) were elevated. Kidney
ultrasound showed 8.3-cm kidneys with loss of corticomedullary
differentiation.
The patient improved after treatment with phenoxymethylpeni-
cillin, although proteinuria and microscopic hematuria persisted.
Four months later, she developed macroscopic hematuria after an
upper respiratory tract infection.
Nine months after presentation, kidney biopsy showed mesan-
gial hypercellularity, segmental endocapillary hypercellularity, and
segmental capillary wall double contours on light microscopy.
Immunoperoxidase staining showed marked granular capillary
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Vernon et alwall and mesangial C3, C9, and CFHR5 deposition (Fig 1A).
Glomerular C1q and immunoglobulins were absent. On electron
microscopy, glomerular basement membranes appeared thickened,
with segmental duplication of the basement membrane and mesan-
gial cell interposition. There were intramembranous electron-
dense deposits with occasional subendothelial deposits, as well as
scattered hump-like subepithelial deposits. Mesangial deposits
were absent. Angiotensin receptor blockade reduced urinary pro-
tein loss and kidney function remained normal.
Twenty months after presentation, a second kidney biopsy (Fig
1A) showed persistent membranoproliferative glomerulonephritis
with tubulointerstitial scarring involving 40% of the cortex.
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Figure 1. (A) Kidney biopsies performed at 9 and 20 mon
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first biopsy specimen. Rabbit anti-human C3 (Dako, www.dak
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122Electron microscopy showed intramembranous electron-dense de-
posits and some mesangial deposits. The findings in both biopsies
are consistent with C3 glomerulopathy with a membranoprolifera-
tive pattern of glomerulonephritis.9 Proteinuria improved with
glucocorticoid therapy. Since the onset of disease, circulating C3
levels have remained low (Fig 1B). She has not developed ocular
drusen or lipodystrophy. C3NeF has been consistently undetect-
able and anti-factor H autoantibodies have not been detected.
To determine whether there was any other serum factor enhanc-
ing C3 activation, we added purified C3 (0.5% solution; Merck,
www.merck.com/index.html) to serum from the index case and
compared its hemolytic activity at 2 and 4 hours with that of
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Glomerulonephritis and CFHR5C3-deficient human serum reconstituted with purified C3 in an
identical fashion. Hemolytic activity at 2 (60% vs 57%) and 4
hours (43% vs 47%) did not differ between the test and control
sera, indicating that there was no evidence of accelerated serum C3
conversion in serum of the index case.
We performed screening for the known genetic causes of alterna-
tive pathway dysregulation. No coding mutations were detected in
the complement genes CD46, complement factor H (CFH), factor
B, factor I, and C3. No copy number variation within the CFH-
CFHR gene locus was seen using a multiplex ligation-dependent
probe amplification assay. CFHR5 gene sequencing revealed a
single heterozygous nucleotide duplication in exon 4 (c.485dupA)
which generates a reading frameshift at amino acid 163 and a
premature stop codon at amino acid position 197 (p.Glu163Argfs*34).
This variant was not detected by sequencing of 198 ethnically matched
DNA samples (obtained from the UK Blood Services Collection of
Common Controls) and was not present in dbSNP (www.ncbi.nlm.ni-
h.gov/snp, accessed October 2011). The healthy mother (I-2) and
sister (II-1), but not the 2 other siblings examined (II-2 and II-4), were
heterozygous for this sequence variant (Fig 1C). The complement
profile of the kindred is shown in Table 1. Serum CFHR5 levels in
unaffected members with the gene variant were within the range seen
in healthy controls (3.4-10.1 g/mL). However, serum CFHR5 level
was decreased in the index case (2.1g/mL). Notably, serum CFHR5
levels also were found to be decreased in individuals with biopsy-
proven C3 glomerulonephritis (Fig 1D).
DISCUSSION
CFHR5 is a member of the CFH family of proteins
encoded within the regulators of complement activation
gene cluster on chromosome 1.10 CFHR5 has been
shown to have complement-regulatory function in vitro11
and to colocalize with complement deposits within the
kidney in a variety of glomerular pathologic states.12
The biological role of CFHR5 is unclear, but it is
Table 1. Co
I-2
CFHR5 sequence variant Yesb
C3 (g/L) 1.43
C4 (g/L) 0.24
CFH (%)c 181
CFI (%)c 174
Total complement hemolytic activity (%)d 108
Alternative pathway hemolytic activity (%)d 92
Serum CFHR5
Absolute amount (g/mL) 5.3
Relative amount (%)e 96.2
Abbreviations: CFH, complement factor H; CFHR5, complem
available (insufficient sample); ND, not detectable.
aIndex patient.
bc.485dupA (p.Glu163Argfs*34); numbering and nomenclatu
cDNA, A in ATG start codon is position 1; for protein, the methion
cNo validated reference range exists for CFH and CFI, so res
apparently healthy controls.
dPercentage of the activity in pooled serum from apparently he
eCompared with the median value in 13 apparently healthy controls,
Am J Kidney Dis. 2012;60(1):121-125postulated to have a physiologic role in the processing of
complement within the kidney.13 This hypothesis has
derived from reports of genetic variation in CFHR5 and
susceptibility to kidney disease. A heterozygous CFHR5
mutation has been shown to be associated with the
development of familial C3 glomerulonephritis in indi-
viduals of Cypriot ancestry,13 and allelic variants of
CFHR5 have been associated with dense deposit dis-
ease.14 Previously published evidence that CFHR5 inter-
acts with glomerular complement12,13 suggests that this
phenomenon contributed to the decrease in serum CFHR5
levels in the index case. Consistent with this hypothesis
was our observation that glomerular CFHR5 was easily
detectable in kidney biopsy specimens from the index
case, median serum CFHR5 levels were low in individu-
als with C3 glomerulonephritis, and serum CFHR5 level
in the index patient was lower than levels in other family
members with the sequence variant, but no kidney dis-
ease. An interesting additional insight based on these
data is that serum CFHR5 levels may be a useful
biomarker of glomerular C3 deposition.
Our report is to our knowledge the first description
of the association of kidney disease with a heterozy-
gous sequence variant causing frameshift and prema-
ture truncation of CFHR5. Interestingly, the same
variant that we describe was reported in an individual
serving as a control in a study investigating the role of
CFHR5 in atypical hemolytic uremic syndrome.15 No
clinical details for this individual were reported. The
presence of the CFHR5 sequence variant in the mother
and sister of the index patient (neither of whom had
ment Profile
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sb No No Yesb
3 1.08 1.14 0.07 0.7-1.7
7 0.21 0.16 0.22 0.16-0.54
2 132 147 148
2 157 186 154
7 99 95 ND 50-150
3 102 95 ND 50-150
8 4.0 NA 2.1 3.4-10.1
.9 72.5 NA 37.3
factor H-related protein 5; CFI, complement factor I; NA, not
lows Human Genome Variation Society recommendations (for
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Vernon et alovert evidence of kidney disease) indicates that
heterozygosity for this CFHR5 sequence variant is not
sufficient to cause kidney disease. We speculate that it
was the presence of both the heterozygous CFHR5
sequence variant and streptococcal infection that pre-
cipitated chronic kidney disease in our index patient.
Interestingly, individuals with other genetic defects
within the CFH gene family are susceptible to exacer-
bation of kidney disease during throat infections.
Synpharyngitic macroscopic hematuria is characteris-
tic of CFHR5 nephropathy13 and common in factor H
deficiency states.16,17 Furthermore, exacerbation of
urinary abnormalities in dense deposit disease has
been associated with streptococcal infection.18 Rarely,
kidney biopsies following APSGN have shown
changes consistent with dense deposit disease.19-21
This raises the difficult question of whether dense
deposit disease is triggered by streptococcal infection
or is a pre-existing lesion that becomes clinically
overt during streptococcal infection. We found one
report describing apparent progression from biopsy-
proven APSGN to dense deposit disease.22 However,
in others, it seems that dense deposit disease may
have predated the episode of APSGN.18,20 Our patient
had no previous evidence of kidney disease, although
it is possible that subclinical disease was present
before the episode of streptococcal infection.
The presence of low serum C3 levels in this case
cannot be explained by the heterozygous sequence
variant in CFHR5 alone because serum C3 levels
were normal in the index patient’s mother and sister,
who also carried the sequence variant. Notably, in
CFHR5 nephropathy, serum C3 levels typically are
normal.13 In contrast, in dense deposit disease, low
serum C3 level is typical and commonly associated
with the presence of C3NeF. However, rarer causes
such as anti–factor B antibodies recently have been
reported.23 C3NeF was repeatedly undetectable in our
case and we could not detect any other factor within
the serum of the index case that was causing acceler-
ated C3 consumption. The serum C3 depletion in our
case most likely results from excessive C3 activation
within the kidney.
In summary, we have identified a heterozygous
sequence variant causing frameshift and premature
truncation of CFHR5 in an individual with chronic
kidney disease after streptococcal infection. We specu-
late that CFHR5 mutations may be a risk factor for the
development of chronic glomerulonephritis after strep-
tococcal infection.
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